Monitor for additional UK reimbursement expansions and any impact on IMCIVREE prescription trends in upcoming quarterly reports.
Drug in focus
RYTM drug pipeline →IMCIVREE
▲ Bullish Named in this press release- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $110.68entry
- T+1 · 12d ago −5.11%α −0.70% · $105.02
- T+5 · 6d ago +1.34%α +2.25% · $112.16
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals announced that NICE issued positive guidance expanding IMCIVREE (setmelanotide) reimbursement to adults with Bardet-Biedl syndrome in England, Wales and Northern Ireland, building on prior pediatric coverage. This regulatory win expands the addressable patient population for IMCIVREE in the UK, supporting the company's commercial momentum in rare obesity indications.
Key Facts
- NICE issued positive guidance for IMCIVREE (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome (BBS)
- Expanded reimbursement allows adults to access funded treatment through the NHS in England, Wales and Northern Ireland
- Prior NICE recommendation (May 2024) covered patients ages 6 to 17 years
- Company market cap is $6.4B with strong institutional support
Financial Impact
Expands UK reimbursement to adult BBS population, incremental revenue potential; no specific dollar amount disclosed
Risk Factors
- No financial terms or revenue guidance provided in the release
- UK market represents a fraction of global opportunity; US and EU remain primary markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395223 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Viewing Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers